Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$752.32 -0.6%	$658.22	$510.05 ▼ $779.03	$46.32B	0.41	353,359 shs	317,666 shs
CRSP CRISPR Therapeutics	$61.19 +5.8%	$56.99	$30.04 ▼ $71.13	$5.26B	1.81	1.71 million shs	4.62 million shs
QGEN QIAGEN	$45.60 +0.5%	$48.38	$37.63 ▼ $51.88	$10.09B	0.64	1.30 million shs	918,209 shs
RGEN Repligen	$119.75 +5.3%	$120.34	$102.96 ▼ $182.52	$6.40B	1.07	675,297 shs	1.36 million shs
TECH Bio-Techne	$51.78 +0.3%	$53.90	$46.01 ▼ $80.95	$8.09B	1.47	2.01 million shs	3.99 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.06%	-1.45%	+15.75%	+39.97%	+40.67%
CRSP CRISPR Therapeutics	+2.81%	+6.91%	-3.16%	+33.92%	+18.19%
QGEN QIAGEN	+0.20%	-4.67%	-8.04%	-2.56%	+0.71%
RGEN Repligen	+0.18%	-5.77%	-8.53%	-6.01%	-18.75%
TECH Bio-Techne	+0.70%	-4.60%	-3.69%	+4.28%	-30.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$752.32 -0.6%	$658.22	$510.05 ▼ $779.03	$46.32B	0.41	353,359 shs	317,666 shs
CRSP CRISPR Therapeutics	$61.19 +5.8%	$56.99	$30.04 ▼ $71.13	$5.26B	1.81	1.71 million shs	4.62 million shs
QGEN QIAGEN	$45.60 +0.5%	$48.38	$37.63 ▼ $51.88	$10.09B	0.64	1.30 million shs	918,209 shs
RGEN Repligen	$119.75 +5.3%	$120.34	$102.96 ▼ $182.52	$6.40B	1.07	675,297 shs	1.36 million shs
TECH Bio-Techne	$51.78 +0.3%	$53.90	$46.01 ▼ $80.95	$8.09B	1.47	2.01 million shs	3.99 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.06%	-1.45%	+15.75%	+39.97%	+40.67%
CRSP CRISPR Therapeutics	+2.81%	+6.91%	-3.16%	+33.92%	+18.19%
QGEN QIAGEN	+0.20%	-4.67%	-8.04%	-2.56%	+0.71%
RGEN Repligen	+0.18%	-5.77%	-8.53%	-6.01%	-18.75%
TECH Bio-Techne	+0.70%	-4.60%	-3.69%	+4.28%	-30.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.04	Buy	$784.32	4.25% Upside
CRSP CRISPR Therapeutics	2.47	Hold	$71.60	17.01% Upside
QGEN QIAGEN	2.27	Hold	$49.69	8.96% Upside
RGEN Repligen	2.67	Moderate Buy	$166.67	39.18% Upside
TECH Bio-Techne	2.77	Moderate Buy	$70.42	35.99% Upside

Current Analyst Ratings Breakdown

Latest TECH, CRSP, ARGX, QGEN, and RGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/15/2025	ARGX argenex	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$700.00 ➝ $918.00
9/12/2025	RGEN Repligen	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$145.00 ➝ $135.00
9/11/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
9/3/2025	RGEN Repligen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$180.00
9/3/2025	TECH Bio-Techne	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
9/2/2025	RGEN Repligen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$205.00
9/2/2025	TECH Bio-Techne	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Sector Perform ➝ Outperform	$61.00 ➝ $73.00
9/2/2025	ARGX argenex	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$880.00 ➝ $887.00
8/26/2025	ARGX argenex	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$818.00
8/26/2025	ARGX argenex	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$750.00 ➝ $820.00
8/26/2025	CRSP CRISPR Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	20.44	$2.95 per share	254.78	$90.49 per share	8.31
CRSP CRISPR Therapeutics	$37.31M	149.16	N/A	N/A	$22.64 per share	2.70
QGEN QIAGEN	$1.98B	5.12	$3.22 per share	14.16	$16.05 per share	2.84
RGEN Repligen	$634.44M	10.62	$3.27 per share	36.61	$35.21 per share	3.40
TECH Bio-Techne	$1.22B	6.66	$2.45 per share	21.11	$12.24 per share	4.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	38.58	69.34	0.82	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	0.00	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
QGEN QIAGEN	$83.59M	$1.69	19.34	18.54	2.40	18.30%	14.77%	8.87%	11/5/2025 (Estimated)
RGEN Repligen	-$25.51M	-$0.25	69.78	50.74	2.10	-2.05%	4.61%	3.24%	11/11/2025 (Estimated)
TECH Bio-Techne	$73.40M	$0.46	29.84	26.28	3.29	6.02%	13.43%	10.32%	10/29/2025 (Estimated)

Latest TECH, CRSP, ARGX, QGEN, and RGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q4 2025	TECH Bio-Techne	$0.50	$0.53	+$0.03	-$0.11	$315.14 million	$316.96 million
8/5/2025	Q2 2025	QGEN QIAGEN	$0.60	$0.60	N/A	$0.44	$523.97 million	$533.54 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/29/2025	Q2 2025	RGEN Repligen	$0.40	$0.37	-$0.03	$0.26	$174.62 million	$182.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
QGEN QIAGEN	$0.25	0.55%	N/A	14.79%	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A
TECH Bio-Techne	$0.32	0.62%	N/A	69.57%	N/A

Latest TECH, CRSP, ARGX, QGEN, and RGEN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	TECH Bio-Techne	quarterly	$0.08	0.59%	8/18/2025	8/18/2025	8/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
CRSP CRISPR Therapeutics	N/A	16.61	16.61
QGEN QIAGEN	0.25	1.61	1.35
RGEN Repligen	0.26	8.59	7.32
TECH Bio-Techne	0.18	3.46	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
CRSP CRISPR Therapeutics	69.20%
QGEN QIAGEN	70.00%
RGEN Repligen	97.64%
TECH Bio-Techne	98.95%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
CRSP CRISPR Therapeutics	4.10%
QGEN QIAGEN	9.00%
RGEN Repligen	1.20%
TECH Bio-Techne	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
QGEN QIAGEN	5,765	222.29 million	202.29 million	Optionable
RGEN Repligen	1,778	56.26 million	55.58 million	Optionable
TECH Bio-Techne	3,100	156.77 million	150.65 million	Optionable

TECH, CRSP, ARGX, QGEN, and RGEN Headlines

Recent News About These Companies

Kera Capital Partners Inc. Invests $276,000 in Bio-Techne Corp $TECH

September 16 at 4:18 AM | marketbeat.com

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Raises Holdings in Bio-Techne Corp $TECH

September 16 at 3:06 AM | marketbeat.com

MDxHealth Completes Acquisition of Exosome Diagnostics from Bio-Techne

September 15 at 5:50 PM | quiverquant.comQ

Here’s Why The Brown Capital Small Company Fund is Re-Evaluating Bio-Techne’s (TECH) Long-Term Growth Profile

September 15 at 9:51 AM | insidermonkey.com

Voya Investment Management LLC Has $34.07 Million Stock Position in Bio-Techne Corp $TECH

September 15 at 4:01 AM | marketbeat.com

Hahn Capital Management LLC Has $4.02 Million Position in Bio-Techne Corp $TECH

September 14 at 6:15 AM | marketbeat.com

Plato Investment Management Ltd Invests $281,000 in Bio-Techne Corp $TECH

September 14 at 4:28 AM | marketbeat.com

The three-year earnings decline is not helping Bio-Techne's (NASDAQ:TECH share price, as stock falls another 5.8% in past week

September 13 at 1:04 PM | finance.yahoo.com

MBB Public Markets I LLC Purchases New Stake in Bio-Techne Corp $TECH

September 13 at 4:28 AM | marketbeat.com

Bio-Techne Corp. stock underperforms Friday when compared to competitors

September 12, 2025 | msn.com

Amundi Lowers Position in Bio-Techne Corp $TECH

September 12, 2025 | marketbeat.com

Royal Bank of Canada Sells 93,248 Shares of Bio-Techne Corp $TECH

September 12, 2025 | marketbeat.com

Why Bio-Techne (TECH) Stock Is Down Today

September 11, 2025 | finance.yahoo.com

Bio-Techne Corp. stock underperforms Wednesday when compared to competitors

September 11, 2025 | msn.com

Bio-Techne Corporation (TECH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 10, 2025 | seekingalpha.com

Fred Alger Management LLC Sells 69,044 Shares of Bio-Techne Corp $TECH

September 10, 2025 | marketbeat.com

Petrus Trust Company LTA Buys Shares of 6,799 Bio-Techne Corp $TECH

September 10, 2025 | marketbeat.com

Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript

September 9, 2025 | seekingalpha.com

ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

September 9, 2025 | prnewswire.com

Bio-Techne Corp $TECH Shares Bought by Select Equity Group L.P.

September 9, 2025 | marketbeat.com

Bio-Techne Corp $TECH Shares Sold by Polar Asset Management Partners Inc.

September 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TECH, CRSP, ARGX, QGEN, and RGEN Company Descriptions

argenex NASDAQ:ARGX

$752.32 -4.51 (-0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$751.33 -0.99 (-0.13%)

As of 06:31 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

CRISPR Therapeutics NASDAQ:CRSP

$61.19 +3.35 (+5.79%)

Closing price 04:00 PM Eastern

Extended Trading

$61.20 +0.01 (+0.01%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

QIAGEN NYSE:QGEN

$45.60 +0.21 (+0.46%)

Closing price 03:59 PM Eastern

Extended Trading

$46.29 +0.69 (+1.51%)

As of 07:28 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen NASDAQ:RGEN

$119.75 +6.01 (+5.28%)

Closing price 04:00 PM Eastern

Extended Trading

$119.80 +0.05 (+0.04%)

As of 04:33 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne NASDAQ:TECH

$51.78 +0.16 (+0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$52.26 +0.48 (+0.93%)

As of 07:55 PM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TECH, CRSP, ARGX, QGEN, and RGEN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TECH, CRSP, ARGX, QGEN, and RGEN Earnings

Compare Dividends

Latest TECH, CRSP, ARGX, QGEN, and RGEN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TECH, CRSP, ARGX, QGEN, and RGEN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TECH, CRSP, ARGX, QGEN, and RGEN Company Descriptions

argenex NASDAQ:ARGX

CRISPR Therapeutics NASDAQ:CRSP

QIAGEN NYSE:QGEN

Repligen NASDAQ:RGEN

Bio-Techne NASDAQ:TECH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools